S&P 500   4,250.20 (+0.49%)
DOW   33,084.75 (+0.25%)
QQQ   358.51 (+1.01%)
AAPL   173.02 (+0.36%)
MSFT   318.36 (+1.59%)
META   305.62 (+1.56%)
GOOGL   135.31 (+2.17%)
AMZN   126.41 (+1.36%)
TSLA   256.74 (+4.14%)
NVDA   440.60 (+1.25%)
NIO   8.76 (+1.74%)
BABA   84.32 (-0.26%)
AMD   102.52 (+2.44%)
T   14.54 (-1.62%)
F   12.06 (-0.08%)
MU   67.93 (+0.15%)
CGC   0.74 (+7.73%)
GE   108.87 (+1.03%)
DIS   79.31 (-0.29%)
AMC   8.03 (+2.29%)
PFE   33.63 (-0.80%)
PYPL   58.24 (+1.64%)
NFLX   379.63 (+0.76%)
S&P 500   4,250.20 (+0.49%)
DOW   33,084.75 (+0.25%)
QQQ   358.51 (+1.01%)
AAPL   173.02 (+0.36%)
MSFT   318.36 (+1.59%)
META   305.62 (+1.56%)
GOOGL   135.31 (+2.17%)
AMZN   126.41 (+1.36%)
TSLA   256.74 (+4.14%)
NVDA   440.60 (+1.25%)
NIO   8.76 (+1.74%)
BABA   84.32 (-0.26%)
AMD   102.52 (+2.44%)
T   14.54 (-1.62%)
F   12.06 (-0.08%)
MU   67.93 (+0.15%)
CGC   0.74 (+7.73%)
GE   108.87 (+1.03%)
DIS   79.31 (-0.29%)
AMC   8.03 (+2.29%)
PFE   33.63 (-0.80%)
PYPL   58.24 (+1.64%)
NFLX   379.63 (+0.76%)
S&P 500   4,250.20 (+0.49%)
DOW   33,084.75 (+0.25%)
QQQ   358.51 (+1.01%)
AAPL   173.02 (+0.36%)
MSFT   318.36 (+1.59%)
META   305.62 (+1.56%)
GOOGL   135.31 (+2.17%)
AMZN   126.41 (+1.36%)
TSLA   256.74 (+4.14%)
NVDA   440.60 (+1.25%)
NIO   8.76 (+1.74%)
BABA   84.32 (-0.26%)
AMD   102.52 (+2.44%)
T   14.54 (-1.62%)
F   12.06 (-0.08%)
MU   67.93 (+0.15%)
CGC   0.74 (+7.73%)
GE   108.87 (+1.03%)
DIS   79.31 (-0.29%)
AMC   8.03 (+2.29%)
PFE   33.63 (-0.80%)
PYPL   58.24 (+1.64%)
NFLX   379.63 (+0.76%)
S&P 500   4,250.20 (+0.49%)
DOW   33,084.75 (+0.25%)
QQQ   358.51 (+1.01%)
AAPL   173.02 (+0.36%)
MSFT   318.36 (+1.59%)
META   305.62 (+1.56%)
GOOGL   135.31 (+2.17%)
AMZN   126.41 (+1.36%)
TSLA   256.74 (+4.14%)
NVDA   440.60 (+1.25%)
NIO   8.76 (+1.74%)
BABA   84.32 (-0.26%)
AMD   102.52 (+2.44%)
T   14.54 (-1.62%)
F   12.06 (-0.08%)
MU   67.93 (+0.15%)
CGC   0.74 (+7.73%)
GE   108.87 (+1.03%)
DIS   79.31 (-0.29%)
AMC   8.03 (+2.29%)
PFE   33.63 (-0.80%)
PYPL   58.24 (+1.64%)
NFLX   379.63 (+0.76%)
NASDAQ:TVTX

Travere Therapeutics (TVTX) SEC Filings & 10K Form

$8.04
-0.51 (-5.96%)
(As of 11:57 AM ET)
Compare
Today's Range
$8.04
▼
$8.55
50-Day Range
$7.64
▼
$17.25
52-Week Range
$7.00
▼
$26.55
Volume
264,807 shs
Average Volume
1.43 million shs
Market Capitalization
$603.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.46
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Recent Travere Therapeutics SEC Filings

Export to Excel
DateFilerForm TypeView
09/21/2023
6:35 AM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/21/2023
6:35 AM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/07/2023
4:00 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K/A
09/05/2023
7:10 PM		Dube Eric M (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2023
7:12 PM		REED ELIZABETH E (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2023
7:13 PM		ROTE WILLIAM E. (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2023
7:15 PM		Cline Christopher R. (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2023
11:54 AM		Dube Eric M (Reporting)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2023
11:43 AM		ROTE WILLIAM E. (Reporting)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2023
11:34 AM		REED ELIZABETH E (Reporting)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2023
7:35 AM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/17/2023
7:07 AM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/10/2023
12:39 PM		ROTE WILLIAM E. (Reporting)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/10/2023
11:58 AM		REED ELIZABETH E (Reporting)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2023
3:46 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/13/2023
4:12 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form DEF 14A
04/12/2023
3:30 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/13/2023
3:30 PM		ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form SC 13G
03/01/2023
4:14 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 424B5
03/01/2023
4:17 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2023
2:22 PM		MACQUARIE GROUP LTD (Filed by)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form SC 13G/A
02/14/2023
12:39 PM		ARMISTICE CAPITAL, LLC (Filed by)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form SC 13G/A
02/10/2023
4:27 PM		GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form SC 13G/A
02/10/2023
10:50 AM		JANUS HENDERSON GROUP PLC (Filed by)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form SC 13G/A
02/09/2023
10:35 AM		Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
02/02/2023
6:08 PM		ROTE WILLIAM E. (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2023
6:11 PM		REED ELIZABETH E (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2023
5:53 PM		Calvin Sandra (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2023
5:58 PM		Dube Eric M (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2023
6:00 PM		Inrig Jula (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2023
6:02 PM		Cline Christopher R. (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2023
6:04 PM		Heerma Peter (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2023
6:05 AM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/28/2022
3:30 PM		ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Travere Therapeutics, Inc. (Subject)
Travere Therapeutics (Subject)
Form SC 13G
10/27/2022
4:01 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/27/2022
3:17 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/13/2022
4:05 PM		Travere Therapeutics, Inc. (Filer)
Travere Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/06/2022
7:10 PM		Heerma Peter (Reporting)
Travere Therapeutics, Inc. (Issuer)
Travere Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies:
SEC Filings Tools:
This page (NASDAQ:TVTX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -